Search Results | Clinical Cancer Research | American Association for Cancer Research

1-20 of 34

Sort by

Sort Order Select

Journal Articles

Integrated DNA and RNA Sequencing Reveals Drivers of Endocrine Resistance in Estrogen Receptor-Positive Breast Cancer

Youli Xia, Xiaping He, Lorna Renshaw, Carlos Martinez-Perez, Charlene Kay, Mark Gray, James Meehan, Joel S. Parker, Charles M. Perou, Lisa A. Carey, J. Michael. Dixon, Arran Turnbull

Clin Cancer Res clincanres.3189.2021-9-2 12:04:46.737.

DOI: https://doi.org/10.1158/1078-0432.CCR-21-3189

Published: 02 June 2022

View article

Includes: Supplementary data

Journal Articles

Independent Validation of the PAM50-Based Chemo-Endocrine Score (CES) in Hormone Receptor–Positive HER2-Positive Breast Cancer Treated with Neoadjuvant Anti–HER2-Based Therapy

Clin Cancer Res (2021) 27 (11): 3116–3125.

DOI: https://doi.org/10.1158/1078-0432.CCR-20-4102

Published: 01 June 2021

View article

Includes: Supplementary data

Journal Articles

Stimulation of Oncogene-Specific Tumor-Infiltrating T Cells through Combined Vaccine and αPD-1 Enable Sustained Antitumor Responses against Established HER2 Breast Cancer

Clin Cancer Res (2020) 26 (17): 4670–4681.

DOI: https://doi.org/10.1158/1078-0432.CCR-20-0389

Published: 01 September 2020

View article

Includes: Supplementary data

Journal Articles

The Immune Microenvironment in Hormone Receptor–Positive Breast Cancer Before and After Preoperative Chemotherapy

Clin Cancer Res (2019) 25 (15): 4644–4655.

DOI: https://doi.org/10.1158/1078-0432.CCR-19-0173

Published: 01 August 2019

View article

Includes: Supplementary data

Journal Articles

Pathological Response and Survival in Triple-Negative Breast Cancer Following Neoadjuvant Carboplatin plus Docetaxel

Clin Cancer Res (2018) 24 (23): 5820–5829.

DOI: https://doi.org/10.1158/1078-0432.CCR-18-0585

Published: 03 December 2018

View article

Includes: Supplementary data

Journal Articles

Integrated Analysis of RNA and DNA from the Phase III Trial CALGB 40601 Identifies Predictors of Response to Trastuzumab-Based Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer

Clin Cancer Res (2018) 24 (21): 5292–5304.

DOI: https://doi.org/10.1158/1078-0432.CCR-17-3431

Published: 01 November 2018

View article

Includes: Supplementary data

Journal Articles

Pathological Response in a Triple-Negative Breast Cancer Cohort Treated with Neoadjuvant Carboplatin and Docetaxel According to Lehmann's Refined Classification

Clin Cancer Res (2018) 24 (8): 1845–1852.

DOI: https://doi.org/10.1158/1078-0432.CCR-17-1912

Published: 12 April 2018

View article

Includes: Supplementary data

Journal Articles

Gene Expression Signatures and Immunohistochemical Subtypes Add Prognostic Value to Each Other in Breast Cancer Cohorts

Arian Lundberg, Linda S. Lindström, J. Chuck Harrell, Claudette Falato, Joseph W. Carlson, Paul K. Wright, Theodoros Foukakis, Charles M. Perou, Kamila Czene, Jonas Bergh, Nicholas P. Tobin

Clin Cancer Res (2017) 23 (24): 7512–7520.

DOI: https://doi.org/10.1158/1078-0432.CCR-17-1535

Published: 14 December 2017

View article

Includes: Supplementary data

Journal Articles

PAM50 Provides Prognostic Information When Applied to the Lymph Node Metastases of Advanced Breast Cancer Patients

Nicholas P. Tobin, Arian Lundberg, Linda S. Lindström, J. Chuck Harrell, Theodoros Foukakis, Lena Carlsson, Zakaria Einbeigi, Barbro K. Linderholm, Niklas Loman, Martin Malmberg, Mårten Fernö, Kamila Czene, Charles M. Perou, Jonas Bergh, Thomas Hatschek

Clin Cancer Res (2017) 23 (23): 7225–7231.

DOI: https://doi.org/10.1158/1078-0432.CCR-17-2301

Published: 30 November 2017

View article

Includes: Supplementary data

Journal Articles

A PAM50-Based Chemoendocrine Score for Hormone Receptor–Positive Breast Cancer with an Intermediate Risk of Relapse

Clin Cancer Res (2017) 23 (12): 3035–3044.

DOI: https://doi.org/10.1158/1078-0432.CCR-16-2092

Published: 14 June 2017

View article

Includes: Supplementary data

Journal Articles

Efficacy of Neoadjuvant Carboplatin plus Docetaxel in Triple-Negative Breast Cancer: Combined Analysis of Two Cohorts

Clin Cancer Res (2017) 23 (3): 649–657.

DOI: https://doi.org/10.1158/1078-0432.CCR-16-0162

Published: 31 January 2017

View article

Includes: Supplementary data

Journal Articles

High Intratumoral Stromal Content Defines Reactive Breast Cancer as a Low-risk Breast Cancer Subtype

Jennifer B. Dennison, Maria Shahmoradgoli, Wenbin Liu, Zhenlin Ju, Funda Meric-Bernstam, Charles M. Perou, Aysegul A. Sahin, Alana Welm, Steffi Oesterreich, Matthew J. Sikora, Robert E. Brown, Gordon B. Mills

Clin Cancer Res (2016) 22 (20): 5068–5078.

DOI: https://doi.org/10.1158/1078-0432.CCR-16-0171

Published: 13 October 2016

View article

Includes: Supplementary data

Journal Articles

CCR 20^th Anniversary Commentary: The Development of Breast Cancer Molecular Subtyping

Torsten O. Nielsen, Charles M. Perou

Clin Cancer Res (2015) 21 (8): 1779–1781.

DOI: https://doi.org/10.1158/1078-0432.CCR-14-2552

Published: 14 April 2015

View article

Journal Articles

Effects of Tumor Microenvironment Heterogeneity on Nanoparticle Disposition and Efficacy in Breast Cancer Tumor Models

Gina Song, David B. Darr, Charlene M. Santos, Mark Ross, Alain Valdivia, Jamie L. Jordan, Bentley R. Midkiff, Stephanie Cohen, Nana Nikolaishvili-Feinberg, C. Ryan Miller, Teresa K. Tarrant, Arlin B. Rogers, Andrew C. Dudley, Charles M. Perou, William C. Zamboni

Clin Cancer Res (2014) 20 (23): 6083–6095.

DOI: https://doi.org/10.1158/1078-0432.CCR-14-0493

Published: 30 November 2014

View article

Includes: Supplementary data

Journal Articles

Predictions of breast cancer local and distant metastasis

Zhiyuan Hu, He Xiaping, Matthew Ewend, Charles M. Perou

Clin Cancer Res (2006) 12 (19_Supplement): A79.

Published: 15 August 2014

View article

Journal Articles

Prognostic B-cell Signatures Using mRNA-Seq in Patients with Subtype-Specific Breast and Ovarian Cancer

Michael D. Iglesia, Benjamin G. Vincent, Joel S. Parker, Katherine A. Hoadley, Lisa A. Carey, Charles M. Perou, Jonathan S. Serody

Clin Cancer Res (2014) 20 (14): 3818–3829.

DOI: https://doi.org/10.1158/1078-0432.CCR-13-3368

Published: 14 July 2014

View article

Includes: Supplementary data

Journal Articles

Predicting Drug Responsiveness in Human Cancers Using Genetically Engineered Mice

Jerry Usary, Wei Zhao, David Darr, Patrick J. Roberts, Mei Liu, Lorraine Balletta, Olga Karginova, Jamie Jordan, Austin Combest, Arlene Bridges, Aleix Prat, Maggie C. U. Cheang, Jason I. Herschkowitz, Jeffrey M. Rosen, William Zamboni, Norman E. Sharpless, Charles M. Perou

Clin Cancer Res (2013) 19 (17): 4889–4899.

DOI: https://doi.org/10.1158/1078-0432.CCR-13-0522

Published: 02 September 2013

View article

Includes: Supplementary data

Journal Articles

Murine Microenvironment Metaprofiles Associate with Human Cancer Etiology and Intrinsic Subtypes

David H. Nguyen, Erik Fredlund, Wei Zhao, Charles M. Perou, Allan Balmain, Jian-Hua Mao, Mary Helen Barcellos-Hoff

Clin Cancer Res (2013) 19 (6): 1353–1362.

DOI: https://doi.org/10.1158/1078-0432.CCR-12-3554

Published: 14 March 2013

View article

Includes: Supplementary data

Journal Articles

Impact of Tumor Microenvironment and Epithelial Phenotypes on Metabolism in Breast Cancer

Heather Ann Brauer, Liza Makowski, Katherine A. Hoadley, Patricia Casbas-Hernandez, Lindsay J. Lang, Erick Romàn-Pèrez, Monica D'Arcy, Alex J. Freemerman, Charles M. Perou, Melissa A. Troester

Clin Cancer Res (2013) 19 (3): 571–585.

DOI: https://doi.org/10.1158/1078-0432.CCR-12-2123

Published: 31 January 2013

View article

Includes: Supplementary data

Journal Articles

Combined PI3K/mTOR and MEK Inhibition Provides Broad Antitumor Activity in Faithful Murine Cancer Models

Patrick J. Roberts, Jerry E. Usary, David B. Darr, Patrick M. Dillon, Adam D. Pfefferle, Martin C. Whittle, James S. Duncan, Soren M. Johnson, Austin J. Combest, Jian Jin, William C. Zamboni, Gary L. Johnson, Charles M. Perou, Norman E. Sharpless

Clin Cancer Res (2012) 18 (19): 5290–5303.

DOI: https://doi.org/10.1158/1078-0432.CCR-12-0563

Published: 30 September 2012

View article

Includes: Supplementary data

NARROW

Integrated DNA and RNA Sequencing Reveals Drivers of Endocrine Resistance in Estrogen Receptor-Positive Breast Cancer

Independent Validation of the PAM50-Based Chemo-Endocrine Score (CES) in Hormone Receptor–Positive HER2-Positive Breast Cancer Treated with Neoadjuvant Anti–HER2-Based Therapy

Stimulation of Oncogene-Specific Tumor-Infiltrating T Cells through Combined Vaccine and αPD-1 Enable Sustained Antitumor Responses against Established HER2 Breast Cancer

The Immune Microenvironment in Hormone Receptor–Positive Breast Cancer Before and After Preoperative Chemotherapy

Pathological Response and Survival in Triple-Negative Breast Cancer Following Neoadjuvant Carboplatin plus Docetaxel

Integrated Analysis of RNA and DNA from the Phase III Trial CALGB 40601 Identifies Predictors of Response to Trastuzumab-Based Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer

Pathological Response in a Triple-Negative Breast Cancer Cohort Treated with Neoadjuvant Carboplatin and Docetaxel According to Lehmann's Refined Classification

Gene Expression Signatures and Immunohistochemical Subtypes Add Prognostic Value to Each Other in Breast Cancer Cohorts

PAM50 Provides Prognostic Information When Applied to the Lymph Node Metastases of Advanced Breast Cancer Patients

A PAM50-Based Chemoendocrine Score for Hormone Receptor–Positive Breast Cancer with an Intermediate Risk of Relapse

Efficacy of Neoadjuvant Carboplatin plus Docetaxel in Triple-Negative Breast Cancer: Combined Analysis of Two Cohorts

High Intratumoral Stromal Content Defines Reactive Breast Cancer as a Low-risk Breast Cancer Subtype

CCR 20^th Anniversary Commentary: The Development of Breast Cancer Molecular Subtyping

Effects of Tumor Microenvironment Heterogeneity on Nanoparticle Disposition and Efficacy in Breast Cancer Tumor Models

Predictions of breast cancer local and distant metastasis

Prognostic B-cell Signatures Using mRNA-Seq in Patients with Subtype-Specific Breast and Ovarian Cancer

Predicting Drug Responsiveness in Human Cancers Using Genetically Engineered Mice

Murine Microenvironment Metaprofiles Associate with Human Cancer Etiology and Intrinsic Subtypes

Impact of Tumor Microenvironment and Epithelial Phenotypes on Metabolism in Breast Cancer

Combined PI3K/mTOR and MEK Inhibition Provides Broad Antitumor Activity in Faithful Murine Cancer Models

Email alerts

AACR Journals

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only